Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial

M. Carcao; M. Zak; F. Abdul Karim; H. Hanabusa; S. Kearney; M.-Y. Lu; P. Persson; S. Rangarajan; E. Santagostino

doi:10.1111/jth.13360

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial

Journal of Thrombosis and Haemostasis ◽

10.1111/jth.13360 ◽

2016 ◽

Vol 14 (8) ◽

pp. 1521-1529 ◽

Cited By ~ 26

Author(s):

M. Carcao ◽

M. Zak ◽

F. Abdul Karim ◽

H. Hanabusa ◽

S. Kearney ◽

...

Keyword(s):

Hemophilia B ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Faculty Opinions recommendation of Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732365471.793564969 ◽

2019 ◽

Author(s):

Anna Rita Migliaccio

Keyword(s):

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC)

10.1158/1538-7445.am2021-ct041 ◽

2021 ◽

Author(s):

Yuankai Shi ◽

Lin Wu ◽

Xinmin Yu ◽

Yan Wang ◽

Puyuan Xing ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Poster: CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01411-7 ◽

2021 ◽

Vol 21 ◽

pp. S224

Author(s):

B Douglas Smith ◽

Jorge E Cortes ◽

Delphine Rea ◽

Michael J Mauro ◽

Pallavi Patwardhan ◽

...

Keyword(s):

Health Care ◽

Myeloid Leukemia ◽

Kinase Inhibitors ◽

Chronic Phase ◽

Health Care Resource ◽

Open Label ◽

Phase 3 ◽

Health Care Resource Utilization ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Lung Cancer ◽

10.1016/j.lungcan.2020.11.013 ◽

2021 ◽

Vol 152 ◽

pp. 7-14

Author(s):

Shun Lu ◽

Jie Wang ◽

Ying Cheng ◽

Tony Mok ◽

Jianhua Chang ◽

...

Keyword(s):

Lung Cancer ◽

Patient Population ◽

Chinese Patient ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

Cancer ◽

10.1002/cncr.34019 ◽

2021 ◽

Author(s):

Hyun Cheol Chung ◽

Yoon‐Koo Kang ◽

Zhendong Chen ◽

Yuxian Bai ◽

Wan Zamaniah Wan Ishak ◽

...

Keyword(s):

Gastroesophageal Junction ◽

Open Label ◽

Phase 3 ◽

Asian Patients ◽

Gastroesophageal Junction Cancer ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30237-5 ◽

2018 ◽

Vol 5 (2) ◽

pp. e73-e81 ◽

Cited By ~ 57

Author(s):

Claire N Harrison ◽

Alessandro M Vannucchi ◽

Uwe Platzbecker ◽

Francisco Cervantes ◽

Vikas Gupta ◽

...

Keyword(s):

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01781-x ◽

2021 ◽

Vol 21 ◽

pp. S334

Author(s):

B Douglas Smith ◽

Jorge E Cortes ◽

Delphine Rea ◽

Michael J Mauro ◽

Pallavi Patwardhan ◽

...

Keyword(s):

Health Care ◽

Myeloid Leukemia ◽

Kinase Inhibitors ◽

Chronic Phase ◽

Health Care Resource ◽

Open Label ◽

Phase 3 ◽

Health Care Resource Utilization ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30312-1 ◽

2017 ◽

Vol 18 (6) ◽

pp. 732-742 ◽

Cited By ~ 169

Author(s):

Véronique Diéras ◽

David Miles ◽

Sunil Verma ◽

Mark Pegram ◽

Manfred Welslau ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Descriptive Analysis ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30027-0 ◽

2019 ◽

Vol 20 (6) ◽

pp. 849-861 ◽

Cited By ~ 74

Author(s):

Cathy Eng ◽

Tae Won Kim ◽

Johanna Bendell ◽

Guillem Argilés ◽

Niall C Tebbutt ◽

...

Keyword(s):

Colorectal Cancer ◽

Randomised Controlled Trial ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated ◽

Randomised Controlled

Download Full-text

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30313-3 ◽

2017 ◽

Vol 18 (6) ◽

pp. 743-754 ◽

Cited By ~ 144

Author(s):

Ian E Krop ◽

Sung-Bae Kim ◽

Antonio Gonzalez Martin ◽

Patricia M LoRusso ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated ◽

Versus Treatment

Download Full-text